[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586342":3},{"organization":4,"outcomesModule":7,"designInfo":98,"detailedDescription":28,"studyPopulation":28,"armGroups":104,"interventions":142,"overallOfficials":28,"centralContacts":148,"locations":154,"responsibleParty":746,"collaborators":28,"id":748,"slug":749,"hasResults":750,"nctId":751,"briefTitle":752,"officialTitle":753,"acronym":28,"eligibilityCriteria":754,"healthyVolunteers":750,"sex":755,"minAge":756,"maxAge":28,"enrollmentInfo":757,"targetDuration":28,"studyType":760,"phases":761,"briefSummary":764,"conditions":765,"keywords":767,"overallStatus":218,"whyStopped":28,"lastUpdateSubmitDate":775,"lastUpdatePostDateStruct":776,"startDateStruct":779,"completionDateStruct":781,"leadSponsor":783,"locationsCount":784},{"fullName":5,"class":6},"Bayer","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":52,"otherOutcomes":28},[9,13,16,19,23,26,30,32,36,39,41,43,45,49],{"measure":10,"description":11,"timeFrame":12},"Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent adverse events (TEAEs)","TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary","From the first administration of study intervention up to 30 days after the last dose of study intervention",{"measure":14,"description":15,"timeFrame":12},"Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent serious adverse events (TESAEs)","TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary",{"measure":17,"description":18,"timeFrame":12},"Dose Escalation (Master and Intervention Cohort 1): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)","TEAEs and TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary",{"measure":20,"description":21,"timeFrame":22},"Dose Escalation (Master and Intervention Cohort 1): Incidence of dose-limiting toxicities (DLTs)","DLTs per participants. DLTs will be graded according to NCI-CTCAE v.5.0","From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)",{"measure":24,"description":25,"timeFrame":22},"Dose Escalation (Master and Intervention Cohort 1): Number of participants with DLTs","Number of participants with at least one DLT",{"measure":27,"description":28,"timeFrame":29},"Dose Escalation (Master and Intervention Cohort 1): Maximum concentration (Cmax) of the respective dosing interval of BAY 3713372",null,"From the first dose of study intervention up to Cycle 2 Day 1 (each cycle is 21 days)",{"measure":31,"description":28,"timeFrame":29},"Dose Escalation (Master and Intervention Cohort 1): Area under the curve (AUC) of the respective dosing interval of BAY 3713372",{"measure":33,"description":34,"timeFrame":35},"Dose Expansion (Master, Intervention Cohorts 1 - 6): Objective response rate (ORR)","Determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)","Approximately 1.5 years",{"measure":37,"description":25,"timeFrame":38},"Dose Expansion (Intervention Cohorts 3, 4 and 6): Number of participants with DLTs","From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)",{"measure":40,"description":11,"timeFrame":12},"Intervention Cohort 7: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)",{"measure":42,"description":11,"timeFrame":12},"Intervention Cohort 7: Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)",{"measure":44,"description":25,"timeFrame":22},"Intervention Cohort 7: Number of participants with DLTs",{"measure":46,"description":47,"timeFrame":48},"Intervention Cohort 7: Brain and brain tumor PK concentration of BAY 3713372","Concentration of BAY 3713372 in enhancing and non-enhancing brain tumor tissue obtained at definitive surgery, with corresponding time-matched plasma concentrations and estimation of tumor-to-plasma exposure ratios","From first dose through day of surgery (approximately 7 ± 2 days)",{"measure":50,"description":51,"timeFrame":48},"Intervention Cohort 7: Tumor tissue SDMA levels","Change in symmetric dimethylarginine (SDMA) levels in brain tumor tissue collected at definitive surgery following neoadjuvant BAY 3713372 treatment, as a pharmacodynamic marker of PRMT5 inhibition",[53,55,59,61,63,65,67,69,71,73,75,77,80,82,84,87,90,93,96],{"measure":54,"description":34,"timeFrame":35},"Dose Escalation (Master and Intervention Cohort 1): Objective response rate (ORR)",{"measure":56,"description":57,"timeFrame":58},"Dose Escalation (Master and Intervention Cohort 1): Duration of response (DOR)","Determined by the investigator according to RECIST v1.1","Approximately 3 years",{"measure":60,"description":57,"timeFrame":58},"Dose Escalation (Master and Intervention Cohort 1): Progression-free survival (PFS)",{"measure":62,"description":28,"timeFrame":35},"Dose Escalation (Master and Intervention Cohort 1): Time to response (TTR)",{"measure":64,"description":11,"timeFrame":12},"Dose Expansion (Master, Intervention Cohorts 1 - 6): Number of participants with treatment-emergent adverse events (TEAEs)",{"measure":66,"description":15,"timeFrame":12},"Dose Expansion (Master, Intervention Cohorts 1 - 6): Number of participants with treatment-emergent serious adverse events (TESAEs)",{"measure":68,"description":18,"timeFrame":12},"Dose Expansion (Master, Intervention Cohorts 1 - 6): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)",{"measure":70,"description":21,"timeFrame":38},"Dose Expansion (Master, Intervention Cohorts 1, 3, 4, and 6): Incidence of dose-limiting toxicities (DLTs)",{"measure":72,"description":57,"timeFrame":58},"Dose Expansion (Master, Intervention Cohorts 1 - 6): Duration of response (DOR)",{"measure":74,"description":57,"timeFrame":58},"Dose Expansion (Master, Intervention Cohorts 1 - 6): Progression-free survival (PFS)",{"measure":76,"description":28,"timeFrame":35},"Dose Expansion (Master, Intervention Cohorts 1 - 6): Time to response (TTR)",{"measure":78,"description":28,"timeFrame":79},"Dose Expansion (Master, Intervention Cohorts 1 - 4, and 6): Maximum concentration (Cmax) of the respective dosing interval of BAY 3713372","From the first dose of study intervention up to Cycle 2 Day 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)",{"measure":81,"description":28,"timeFrame":79},"Dose Expansion (Master, Intervention Cohorts 1 - 4, and 6): Area under the curve (AUC) of the respective dosing interval of BAY 3713372",{"measure":83,"description":28,"timeFrame":58},"Dose Expansion (Part A of Intenvention Cohort 2): Time to CNS progression (CNS-TTP)",{"measure":85,"description":86,"timeFrame":35},"Dose Expansion (Part B of Intervention Cohort 2): CNS-ORR for active brain metastases","CNS-ORR: CNS objective response rate",{"measure":88,"description":89,"timeFrame":58},"Dose Expansion (Part B of Intervention Cohort 2): CNS-DOR for active brain metastases","CNS-DOR: Duration of CNS response",{"measure":91,"description":92,"timeFrame":58},"Dose Expansion (Part B of Intervention Cohort 2): CNS-PFS for active brain metastases","CNS-PFS: Survival without CNS progression",{"measure":94,"description":95,"timeFrame":35},"Dose Expansion (Part B of Intervention Cohort 2): CNS-TTR for active brain metastases","CNS-TTR: Time to CNS response",{"measure":97,"description":28,"timeFrame":35},"Dose Expansion (Part B of Intervention Cohort 2): CNS-related disease control rate (CNS-DCR) in active brain metastases",{"allocation":99,"interventionModel":100,"interventionModelDescription":28,"primaryPurpose":101,"observationalModel":28,"timePerspective":28,"maskingInfo":102},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":103,"maskingDescription":28,"whoMasked":28},"NONE",[105,111,115,119,123,127,130,134,138],{"label":106,"type":107,"description":108,"interventionNames":109},"Dose Escalation (Intervention Cohort 1)","EXPERIMENTAL","For the escalation part, different dose levels of BAY 3713372 administered as monotherapy are planned.",[110],"Drug: BAY 3713372",{"label":112,"type":107,"description":113,"interventionNames":114},"Backfill cohorts in Intervention Cohort 1 (Dose Escalation)","Backfill cohorts may be initiated concurrently with dose escalation cohorts to generate additional safety, pharmacokinetic, and pharmacodynamic data to facilitate the selection of the optimal doses for use in further development.",[110],{"label":116,"type":107,"description":117,"interventionNames":118},"Dose Expansion (Intervention Cohort 1)","Dose expansion with BAY 3713372 monotherapy in selected participants with MTAP-deleted solid tumors.",[110],{"label":120,"type":107,"description":121,"interventionNames":122},"Dose Expansion (Intervention Cohort 2)","Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted non-small cell lung cancer (NSCLC).",[110],{"label":124,"type":107,"description":125,"interventionNames":126},"Dose Expansion (Intervention Cohort 3)","Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC.",[110],{"label":128,"type":107,"description":125,"interventionNames":129},"Dose Expansion (Intervention Cohort 4)",[110],{"label":131,"type":107,"description":132,"interventionNames":133},"Dose Expansion (Intervention Cohort 5)","Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC).",[110],{"label":135,"type":107,"description":136,"interventionNames":137},"Dose Expansion (Intervention Cohort 6)","Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted PDAC.",[110],{"label":139,"type":107,"description":140,"interventionNames":141},"Window-of-opportunity trial in participants with MTAP-deleted GBM (Intervention Cohort 7)","A surgical window-of-opportunity trial of BAY 3713372 alone in participants with MTAP-deleted glioblastoma (GBM).",[110],[143],{"type":144,"name":145,"description":146,"armGroupLabels":147,"otherNames":28},"DRUG","BAY 3713372","Daily oral administration",[112,106,116,120,124,128,131,135,139],[149],{"name":150,"role":151,"phone":152,"phoneExt":28,"email":153},"Bayer Clinical Trials Contact","CONTACT","18888422937","clinical-trials-contact@bayer.com",[155,169,179,188,197,206,216,226,236,246,252,262,271,277,287,297,306,316,328,337,346,355,366,376,386,395,407,413,423,433,443,454,464,476,486,497,506,515,521,530,542,552,562,567,572,576,588,598,608,618,624,630,641,647,657,666,675,684,693,702,714,724,736],{"facility":156,"status":157,"city":158,"state":159,"zip":160,"country":161,"countryCode":162,"cosmosGeoPoint":163,"geoPoint":168,"contacts":28},"UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital","NOT_YET_RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":164,"coordinates":165},"Point",[166,167],-86.80249,33.52066,{"lat":167,"lon":166},{"facility":170,"status":157,"city":171,"state":172,"zip":173,"country":161,"countryCode":162,"cosmosGeoPoint":174,"geoPoint":178,"contacts":28},"City of Hope - Duarte Cancer Center","Duarte","California","91010",{"type":164,"coordinates":175},[176,177],-117.97729,34.13945,{"lat":177,"lon":176},{"facility":180,"status":157,"city":181,"state":172,"zip":182,"country":161,"countryCode":162,"cosmosGeoPoint":183,"geoPoint":187,"contacts":28},"UCLA Health Bowyer Oncology Center","Los Angeles","90095",{"type":164,"coordinates":184},[185,186],-118.24368,34.05223,{"lat":186,"lon":185},{"facility":189,"status":157,"city":190,"state":172,"zip":191,"country":161,"countryCode":162,"cosmosGeoPoint":192,"geoPoint":196,"contacts":28},"UCSF Helen Diller Medical Center at Parnassus Heights - Neurology","San Francisco","94143",{"type":164,"coordinates":193},[194,195],-122.41942,37.77493,{"lat":195,"lon":194},{"facility":198,"status":157,"city":199,"state":172,"zip":200,"country":161,"countryCode":162,"cosmosGeoPoint":201,"geoPoint":205,"contacts":28},"Stanford University Medical Center - Neurology","Stanford","94305",{"type":164,"coordinates":202},[203,204],-122.16608,37.42411,{"lat":204,"lon":203},{"facility":207,"status":157,"city":208,"state":209,"zip":210,"country":161,"countryCode":162,"cosmosGeoPoint":211,"geoPoint":215,"contacts":28},"UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center","Aurora","Colorado","80045",{"type":164,"coordinates":212},[213,214],-104.83192,39.72943,{"lat":214,"lon":213},{"facility":217,"status":218,"city":219,"state":209,"zip":220,"country":161,"countryCode":162,"cosmosGeoPoint":221,"geoPoint":225,"contacts":28},"Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's","RECRUITING","Denver","80218",{"type":164,"coordinates":222},[223,224],-104.9847,39.73915,{"lat":224,"lon":223},{"facility":227,"status":218,"city":228,"state":229,"zip":230,"country":161,"countryCode":162,"cosmosGeoPoint":231,"geoPoint":235,"contacts":28},"Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona","Orlando","Florida","32827",{"type":164,"coordinates":232},[233,234],-81.37924,28.53834,{"lat":234,"lon":233},{"facility":237,"status":218,"city":238,"state":239,"zip":240,"country":161,"countryCode":162,"cosmosGeoPoint":241,"geoPoint":245,"contacts":28},"Massachusetts General Hospital - Neurology","Boston","Massachusetts","02114",{"type":164,"coordinates":242},[243,244],-71.05977,42.35843,{"lat":244,"lon":243},{"facility":247,"status":218,"city":238,"state":239,"zip":248,"country":161,"countryCode":162,"cosmosGeoPoint":249,"geoPoint":251,"contacts":28},"Dana-Farber Cancer Institute - Oncology Department","02215",{"type":164,"coordinates":250},[243,244],{"lat":244,"lon":243},{"facility":253,"status":218,"city":254,"state":255,"zip":256,"country":161,"countryCode":162,"cosmosGeoPoint":257,"geoPoint":261,"contacts":28},"START | Midwest","Grand Rapids","Michigan","49546",{"type":164,"coordinates":258},[259,260],-85.66809,42.96336,{"lat":260,"lon":259},{"facility":263,"status":157,"city":264,"state":264,"zip":265,"country":161,"countryCode":162,"cosmosGeoPoint":266,"geoPoint":270,"contacts":28},"Icahn School of Medicine at Mount Sinai - Oncology","New York","10029",{"type":164,"coordinates":267},[268,269],-74.00597,40.71427,{"lat":269,"lon":268},{"facility":272,"status":218,"city":264,"state":264,"zip":273,"country":161,"countryCode":162,"cosmosGeoPoint":274,"geoPoint":276,"contacts":28},"Memorial Sloan Kettering Cancer Center New York - Main Campus","10065",{"type":164,"coordinates":275},[268,269],{"lat":269,"lon":268},{"facility":278,"status":218,"city":279,"state":280,"zip":281,"country":161,"countryCode":162,"cosmosGeoPoint":282,"geoPoint":286,"contacts":28},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":164,"coordinates":283},[284,285],-86.78444,36.16589,{"lat":285,"lon":284},{"facility":288,"status":218,"city":289,"state":290,"zip":291,"country":161,"countryCode":162,"cosmosGeoPoint":292,"geoPoint":296,"contacts":28},"NEXT Dallas - Oncology Department","Irving","Texas","75039",{"type":164,"coordinates":293},[294,295],-96.94889,32.81402,{"lat":295,"lon":294},{"facility":298,"status":218,"city":299,"state":290,"zip":300,"country":161,"countryCode":162,"cosmosGeoPoint":301,"geoPoint":305,"contacts":28},"START | San Antonio","San Antonio","78229",{"type":164,"coordinates":302},[303,304],-98.49363,29.42412,{"lat":304,"lon":303},{"facility":307,"status":218,"city":308,"state":309,"zip":310,"country":161,"countryCode":162,"cosmosGeoPoint":311,"geoPoint":315,"contacts":28},"Froedtert Hospital - Clinical Cancer Center","Milwaukee","Wisconsin","53226",{"type":164,"coordinates":312},[313,314],-87.90647,43.0389,{"lat":314,"lon":313},{"facility":317,"status":218,"city":318,"state":319,"zip":320,"country":321,"countryCode":322,"cosmosGeoPoint":323,"geoPoint":327,"contacts":28},"Chris O'Brien Lifehouse","Camperdown","New South Wales","2050","Australia","AU",{"type":164,"coordinates":324},[325,326],151.17642,-33.88965,{"lat":326,"lon":325},{"facility":329,"status":218,"city":330,"state":319,"zip":331,"country":321,"countryCode":322,"cosmosGeoPoint":332,"geoPoint":336,"contacts":28},"Concord Repatriation General Hospital (CRGH) (Concord Hospital) - Concord Cancer Centre","Concord","2139",{"type":164,"coordinates":333},[334,335],151.10381,-33.84722,{"lat":335,"lon":334},{"facility":338,"status":157,"city":339,"state":319,"zip":340,"country":321,"countryCode":322,"cosmosGeoPoint":341,"geoPoint":345,"contacts":28},"Northern Hospital","Epping","3076",{"type":164,"coordinates":342},[343,344],151.08184,-33.77271,{"lat":344,"lon":343},{"facility":347,"status":218,"city":348,"state":319,"zip":349,"country":321,"countryCode":322,"cosmosGeoPoint":350,"geoPoint":354,"contacts":28},"Calvary Mater Hospital Newcastle - Oncology","Waratah","2298",{"type":164,"coordinates":351},[352,353],151.72647,-32.90667,{"lat":353,"lon":352},{"facility":356,"status":218,"city":357,"state":357,"zip":358,"country":359,"countryCode":360,"cosmosGeoPoint":361,"geoPoint":365,"contacts":28},"Antwerp University Hospital | Oncology Department","Antwerp","2650","Belgium","BE",{"type":164,"coordinates":362},[363,364],4.40026,51.22047,{"lat":364,"lon":363},{"facility":367,"status":218,"city":368,"state":369,"zip":370,"country":359,"countryCode":360,"cosmosGeoPoint":371,"geoPoint":375,"contacts":28},"Ghent University Hospital | Drug Research Unit Department","Ghent","East Flanders","9000",{"type":164,"coordinates":372},[373,374],3.71667,51.05,{"lat":374,"lon":373},{"facility":377,"status":157,"city":378,"state":379,"zip":380,"country":359,"countryCode":360,"cosmosGeoPoint":381,"geoPoint":385,"contacts":28},"UZ Leuven Gasthuisberg - Pneumology Department","Leuven","Flemish Brabant","3000",{"type":164,"coordinates":382},[383,384],4.70093,50.87959,{"lat":384,"lon":383},{"facility":387,"status":218,"city":388,"state":388,"zip":389,"country":359,"countryCode":360,"cosmosGeoPoint":390,"geoPoint":394,"contacts":28},"Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology","Liège","4000",{"type":164,"coordinates":391},[392,393],5.56749,50.63373,{"lat":393,"lon":392},{"facility":396,"status":218,"city":397,"state":398,"zip":399,"country":400,"countryCode":401,"cosmosGeoPoint":402,"geoPoint":406,"contacts":28},"Beijing Cancer Hospital - Oncology Department","Beijing","Beijing Municipality","100142","China","CN",{"type":164,"coordinates":403},[404,405],116.39723,39.9075,{"lat":405,"lon":404},{"facility":408,"status":157,"city":397,"state":398,"zip":409,"country":400,"countryCode":401,"cosmosGeoPoint":410,"geoPoint":412,"contacts":28},"Beijing chest hospital, Capital Medical University","101149",{"type":164,"coordinates":411},[404,405],{"lat":405,"lon":404},{"facility":414,"status":218,"city":415,"state":416,"zip":417,"country":400,"countryCode":401,"cosmosGeoPoint":418,"geoPoint":422,"contacts":28},"Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.","Wuhan","Hubei","430075",{"type":164,"coordinates":419},[420,421],114.26667,30.58333,{"lat":421,"lon":420},{"facility":424,"status":157,"city":425,"state":426,"zip":427,"country":400,"countryCode":401,"cosmosGeoPoint":428,"geoPoint":432,"contacts":28},"Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University","Nanjing","Jiangsu","210029",{"type":164,"coordinates":429},[430,431],118.77778,32.06167,{"lat":431,"lon":430},{"facility":434,"status":157,"city":435,"state":436,"zip":437,"country":400,"countryCode":401,"cosmosGeoPoint":438,"geoPoint":442,"contacts":28},"Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department","Hangzhou","Zhejiang","310016",{"type":164,"coordinates":439},[440,441],120.16142,30.29365,{"lat":441,"lon":440},{"facility":444,"status":218,"city":445,"state":446,"zip":447,"country":448,"countryCode":28,"cosmosGeoPoint":449,"geoPoint":453,"contacts":28},"Fakultní nemocnice Olomouc - Onkologická klinika","Olomouc","Olomouc Region","779 00","Czechia",{"type":164,"coordinates":450},[451,452],17.25175,49.59552,{"lat":452,"lon":451},{"facility":455,"status":218,"city":456,"state":457,"zip":458,"country":448,"countryCode":28,"cosmosGeoPoint":459,"geoPoint":463,"contacts":28},"Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP)","Brno","South Moravian","602 00",{"type":164,"coordinates":460},[461,462],16.60796,49.19522,{"lat":462,"lon":461},{"facility":465,"status":218,"city":466,"state":467,"zip":468,"country":469,"countryCode":470,"cosmosGeoPoint":471,"geoPoint":475,"contacts":28},"Rigshospitalet Copenhagen University Hospital | Oncology Department","Copenhagen","Capital Region \u002F Region Hovedstaden","2100","Denmark","DK",{"type":164,"coordinates":472},[473,474],12.56553,55.67594,{"lat":474,"lon":473},{"facility":477,"status":218,"city":478,"state":479,"zip":480,"country":469,"countryCode":470,"cosmosGeoPoint":481,"geoPoint":485,"contacts":28},"Odense University Hospital | Svendborg Sygehus - Oncology Department","Odense","Region of Southern Denmark \u002F Region Syddanmark","5000",{"type":164,"coordinates":482},[483,484],10.38831,55.39594,{"lat":484,"lon":483},{"facility":487,"status":218,"city":488,"state":28,"zip":489,"country":490,"countryCode":491,"cosmosGeoPoint":492,"geoPoint":496,"contacts":28},"Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati","Aviano","33081","Italy","IT",{"type":164,"coordinates":493},[494,495],12.59472,46.07056,{"lat":495,"lon":494},{"facility":498,"status":218,"city":499,"state":28,"zip":500,"country":490,"countryCode":491,"cosmosGeoPoint":501,"geoPoint":505,"contacts":28},"Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1","Milan","20133",{"type":164,"coordinates":502},[503,504],12.59836,42.78235,{"lat":504,"lon":503},{"facility":507,"status":218,"city":508,"state":28,"zip":509,"country":490,"countryCode":491,"cosmosGeoPoint":510,"geoPoint":514,"contacts":28},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I","Roma","00128",{"type":164,"coordinates":511},[512,513],11.10642,44.99364,{"lat":513,"lon":512},{"facility":516,"status":157,"city":508,"state":28,"zip":517,"country":490,"countryCode":491,"cosmosGeoPoint":518,"geoPoint":520,"contacts":28},"I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione","00144",{"type":164,"coordinates":519},[512,513],{"lat":513,"lon":512},{"facility":522,"status":218,"city":523,"state":28,"zip":524,"country":490,"countryCode":491,"cosmosGeoPoint":525,"geoPoint":529,"contacts":28},"Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia","Rozzano","20089",{"type":164,"coordinates":526},[527,528],9.1559,45.38193,{"lat":528,"lon":527},{"facility":531,"status":218,"city":532,"state":533,"zip":534,"country":535,"countryCode":536,"cosmosGeoPoint":537,"geoPoint":541,"contacts":28},"Nagoya University Hospital","Nagoya","Aichi-ken","466-8560","Japan","JP",{"type":164,"coordinates":538},[539,540],136.90641,35.18147,{"lat":540,"lon":539},{"facility":543,"status":157,"city":544,"state":545,"zip":546,"country":535,"countryCode":536,"cosmosGeoPoint":547,"geoPoint":551,"contacts":28},"National Cancer Center Hospital East","Kashiwa","Chiba","277-8577",{"type":164,"coordinates":548},[549,550],139.97732,35.86224,{"lat":550,"lon":549},{"facility":553,"status":218,"city":554,"state":555,"zip":556,"country":535,"countryCode":536,"cosmosGeoPoint":557,"geoPoint":561,"contacts":28},"Kindai University Hospital","Sakai","Osaka","590-0197",{"type":164,"coordinates":558},[559,560],135.46653,34.58216,{"lat":560,"lon":559},{"facility":563,"status":218,"city":564,"state":565,"zip":566,"country":535,"countryCode":536,"cosmosGeoPoint":28,"geoPoint":28,"contacts":28},"Shizuoka Cancer Center","Sunto","Shizuoka","411-8777",{"facility":568,"status":218,"city":569,"state":570,"zip":571,"country":535,"countryCode":536,"cosmosGeoPoint":28,"geoPoint":28,"contacts":28},"National Cancer Center Hospital","Chuo-ku","Tokyo","104-0045",{"facility":573,"status":218,"city":574,"state":570,"zip":575,"country":535,"countryCode":536,"cosmosGeoPoint":28,"geoPoint":28,"contacts":28},"The Cancer Institute Hospital of JFCR","Koto-ku","135-8550",{"facility":577,"status":218,"city":578,"state":579,"zip":580,"country":581,"countryCode":582,"cosmosGeoPoint":583,"geoPoint":587,"contacts":28},"Nederlands Kanker Instituut","Amsterdam","North Holland","1066 CX","Netherlands","NL",{"type":164,"coordinates":584},[585,586],4.88969,52.37403,{"lat":586,"lon":585},{"facility":589,"status":218,"city":590,"state":591,"zip":592,"country":581,"countryCode":582,"cosmosGeoPoint":593,"geoPoint":597,"contacts":28},"Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center","Groningen","Provincie Groningen","9713 GZ",{"type":164,"coordinates":594},[595,596],6.56667,53.21917,{"lat":596,"lon":595},{"facility":599,"status":157,"city":600,"state":601,"zip":602,"country":581,"countryCode":582,"cosmosGeoPoint":603,"geoPoint":607,"contacts":28},"Erasmus Medisch Centrum","Rotterdam","South Holland","3015 CE",{"type":164,"coordinates":604},[605,606],4.47917,51.9225,{"lat":606,"lon":605},{"facility":609,"status":218,"city":610,"state":28,"zip":611,"country":610,"countryCode":612,"cosmosGeoPoint":613,"geoPoint":617,"contacts":28},"National University Hospital Medical Centre","Singapore","119074","SG",{"type":164,"coordinates":614},[615,616],103.85007,1.28967,{"lat":616,"lon":615},{"facility":619,"status":218,"city":610,"state":28,"zip":620,"country":610,"countryCode":612,"cosmosGeoPoint":621,"geoPoint":623,"contacts":28},"National Cancer Center Singapore - Oncology Department","168583",{"type":164,"coordinates":622},[615,616],{"lat":616,"lon":615},{"facility":625,"status":218,"city":610,"state":28,"zip":626,"country":610,"countryCode":612,"cosmosGeoPoint":627,"geoPoint":629,"contacts":28},"Icon Cancer Centre","217562",{"type":164,"coordinates":628},[615,616],{"lat":616,"lon":615},{"facility":631,"status":218,"city":632,"state":632,"zip":633,"country":634,"countryCode":635,"cosmosGeoPoint":636,"geoPoint":640,"contacts":28},"Hospital Hm Nou Delfos | Oncologia","Barcelona","08023","Spain","ES",{"type":164,"coordinates":637},[638,639],2.15899,41.38879,{"lat":639,"lon":638},{"facility":642,"status":218,"city":632,"state":632,"zip":643,"country":634,"countryCode":635,"cosmosGeoPoint":644,"geoPoint":646,"contacts":28},"Hospital Universitari Vall D Hebron | Oncologia","08035",{"type":164,"coordinates":645},[638,639],{"lat":639,"lon":638},{"facility":648,"status":218,"city":649,"state":650,"zip":651,"country":634,"countryCode":635,"cosmosGeoPoint":652,"geoPoint":656,"contacts":28},"Hospital San Pedro | Oncologia","Logroño","La Rioja","26006",{"type":164,"coordinates":653},[654,655],-2.45115,42.46615,{"lat":655,"lon":654},{"facility":658,"status":218,"city":659,"state":659,"zip":660,"country":634,"countryCode":635,"cosmosGeoPoint":661,"geoPoint":665,"contacts":28},"Hospital Universitario Fundacion Jimenez Diaz | Oncologia","Madrid","28040",{"type":164,"coordinates":662},[663,664],-3.70256,40.4165,{"lat":664,"lon":663},{"facility":667,"status":218,"city":668,"state":659,"zip":669,"country":634,"countryCode":635,"cosmosGeoPoint":670,"geoPoint":674,"contacts":28},"NEXT - Hospital Universitario Quironsalud Madrid | Oncologia","Pozuelo de Alarcón","28223",{"type":164,"coordinates":671},[672,673],-3.81338,40.43293,{"lat":673,"lon":672},{"facility":676,"status":218,"city":677,"state":677,"zip":678,"country":634,"countryCode":635,"cosmosGeoPoint":679,"geoPoint":683,"contacts":28},"Hospital Universitario Virgen De La Victoria | Oncologia","Málaga","29010",{"type":164,"coordinates":680},[681,682],-4.42034,36.72016,{"lat":682,"lon":681},{"facility":685,"status":218,"city":686,"state":686,"zip":687,"country":634,"countryCode":635,"cosmosGeoPoint":688,"geoPoint":692,"contacts":28},"Hospital Clinico Universitario De Valencia | Oncologia","Valencia","46010",{"type":164,"coordinates":689},[690,691],-0.37966,39.47391,{"lat":691,"lon":690},{"facility":694,"status":218,"city":695,"state":28,"zip":696,"country":634,"countryCode":635,"cosmosGeoPoint":697,"geoPoint":701,"contacts":28},"Clinica Universidad De Navarra | Pamplona | Oncologia","Pamplona","31008",{"type":164,"coordinates":698},[699,700],-1.64323,42.81687,{"lat":700,"lon":699},{"facility":703,"status":218,"city":704,"state":705,"zip":706,"country":707,"countryCode":708,"cosmosGeoPoint":709,"geoPoint":713,"contacts":28},"Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC","Stockholm","Stockholm County","171 76","Sweden","SE",{"type":164,"coordinates":710},[711,712],18.06871,59.32938,{"lat":712,"lon":711},{"facility":715,"status":218,"city":716,"state":717,"zip":718,"country":707,"countryCode":708,"cosmosGeoPoint":719,"geoPoint":723,"contacts":28},"Sahlgrenska Universitetssjukhuset - Sahlgrenska Sjukhuset - Klinisk prövningsenhet Fas I\u002FFIH","Gothenburg","Västra Götaland County","413 46",{"type":164,"coordinates":720},[721,722],11.96679,57.70716,{"lat":722,"lon":721},{"facility":725,"status":218,"city":726,"state":727,"zip":728,"country":729,"countryCode":730,"cosmosGeoPoint":731,"geoPoint":735,"contacts":28},"The Christie Hospital | Experimental Cancer Medicine Team","Manchester","Greater Manchester","M20 4BX","United Kingdom","UK",{"type":164,"coordinates":732},[733,734],-2.23743,53.48095,{"lat":734,"lon":733},{"facility":737,"status":218,"city":738,"state":739,"zip":740,"country":729,"countryCode":730,"cosmosGeoPoint":741,"geoPoint":745,"contacts":28},"The Royal Marsden Hospital (Sutton, Surrey) | Oak Foundation Drug Development Unit","Sutton","Surrey","SM2 5PT",{"type":164,"coordinates":742},[743,744],-0.2,51.35,{"lat":744,"lon":743},{"type":747,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100586342","phase-1-a-study-of-prmt5-inhibitor-bay-3713372-in-participants-with-mtap-deleted-solid-tumors-100586342",false,"NCT06914128","A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors","A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of BAY 3713372, a Novel 2nd Generation PRMT5 Inhibitor, in Participants With MTAP-deleted Solid Tumors.","Inclusion Criteria:\n\n* Participant must be ≥ 18 years old of age, or the legal age of consent in the jurisdiction of the country in which the study takes place, at the time of signing the informed consent.\n* At least one measurable lesion that would qualify as target lesion by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).\n* Homozygous MTAP-deletion identified through molecular testing from a locally certified laboratory.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion Criteria:\n\n* Previous additional cancer other than the one evaluated in this study within the past 2 years except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder tumors, localized prostate cancer or other tumors that in the opinion of the investigator, are considered cured or not immediately life-threatening, and will not interfere with the scientific goals of this study.\n* A marked prolongation of QT\u002FQTc interval at screening (e.g., repeated demonstration of a QTc interval \\>450 ms). Participants with permanent pacemakers (i.e., a paced rhythm) may be eligible based on the investigator's clinical assessment and discretion.\n* Cardiac history comprising:\n\n  * History of congestive heart failure Class \\>II according to the New York Heart Association Functional Classification.\n  * Myocardial infarction less than 6 months before the start of study intervention.\n  * Serious cardiac arrhythmias requiring treatment or any clinically important abnormalities in rhythm, conduction or morphology on resting ECG with the exception of atrial fibrillation which is well-controlled and requires only digoxin or beta blockers.\n* Unstable angina within 4 weeks before start of study intervention.","ALL","18 Years",{"count":758,"type":759},450,"ESTIMATED","INTERVENTIONAL",[762,763],"PHASE1","PHASE2","The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells.\n\nThe main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors.\n\nFor this, the researchers will study and analyze:\n\n* the number of participants who have adverse events (AEs) after receiving different doses of BAY 3713372 and the AE's severity.\n* the number of participants who experience dose-limiting toxicities (DLTs) after receiving different doses of BAY 3713372, the DLT's severity and how often they happened. A DLT is a pre-defined medical problem caused by a specific dose of a drug that is too severe to continue using that dose.\n* the total amount of BAY 3713372 in participants' blood (also called AUC) over time after single and multiple doses.\n* the highest level of BAY 3713372 in participants' blood (also called Cmax) after single and multiple doses.\n\nOther than the main objective, researchers will also check for the number of participants who show a response to treatment and how long they live without the cancer getting worse.\n\nThe study participants will take part in one of the eight distinct groups or \"intervention cohorts\" of the study. The study will start with a dose escalation phase where distinct groups of participants will receive different doses of BAY 3713372 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3713372 alone or with other treatments in a dose expansion phase.\n\nParticipants may take the study treatment as long as they benefit from the treatment without any severe medical problems.\n\nParticipants will visit the study site:\n\n* at least twice before the treatment starts\n* multiple times when they start taking the treatment\n* once after 30 days of receiving the last dose and every 9 weeks after that until the cancer worsens, or the participant stops for any other reason\n\nDuring the study, the doctors and their study team will:\n\n* check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram\n* check if the participants' cancer has grown and\u002For spread using computed tomography (CT) or magnetic resonance imaging (MRI) and, if needed, bone scan\n* take tumor samples\n\nThe study doctors and their team will contact the participants every 3 months until 2 years after the last participant's last dose or the end of the study to learn about the participant's health.",[766],"MTAP-deleted Solid Tumors",[768,769,770,771,772,773,774],"Solid Tumors","Non-small cell lung cancer","NSCLC","Pancreatic adenocarcinoma","PDAC","Glioblastoma","GBM","2026-09-09",{"date":777,"type":778},"2026-09-10","ACTUAL",{"date":780,"type":778},"2025-03-21",{"date":782,"type":759},"2029-06-18",{"name":5,"class":6},63]